Akèy › Kansè ovè › Texas › Fort Worth
Etid klinik pou Kansè ovè nan Fort Worth, TX
17 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Fort Worth (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- START Center for Clinical Research, Fort Worth
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Texas Oncology - Fort Worth Cancer Center /ID# 275043, Fort Worth
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Ap rekriteFaz 3
- Texas Oncology - DFW ( Site 8005), Fort Worth
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ap rekriteFaz 2
- Texas Oncology - Fort Worth Cancer Center /ID# 277989, Fort Worth
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 3
- Jps Health Network, Fort Worth
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- Start Dfw, Fort Worth
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Start - Dfw, Fort Worth
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ap rekriteFaz 3
- Texas Oncology - DFW ( Site 8001), Fort Worth
Study of NTB-928 in R/R OC
Ap rekriteFaz 1
- Start Ccbd, Llc, Fort Worth
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Ap rekriteFaz 2/3
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Ap rekriteFaz 1
- Xencor Investigative Site, Fort Worth
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- START Center for Cancer Research - Texas, Fort Worth
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Texas Oncology, Fort Worth
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Ap rekriteFaz 2/3
- Texas Oncology Paris, Fort Worth
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Ap rekriteFaz 1
- START Dallas, Fort Worth
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Ap rekriteFaz 2
- SCRI - Texas Oncology, Fort Worth
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan Fort Worth
- Kansè Poumon ki pa ti selil18 etid
- Kansè Endomèt12 etid
- Kansè nan tete11 etid
- Kansè (tout kalite)9 etid
- Kansè pwostat9 etid
- Ensifizyans kadyak7 etid
- Kansè kolorektal7 etid
- Kansè tete negatif triple7 etid
- Kansè Metastatik7 etid
- Kansè renn (Kasinom selil renn)7 etid
- Kolit Ulseratif7 etid
- Degeneresans makile7 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.